DSR-29133, a potent selective TLR7 agonist, can induce anti-tumor immune responses that can be further enhanced through combination with low-dose fractionated radiotherapy in different murine solid tumor models, including CRC (CT26) [61]. This evidence concerns the gene TLR7 and colorectal carcinoma.